Day: February 13, 2023

Great Elm Group Reports Fiscal 2023 Second Quarter Financial Results

Great Elm Group Reports Fiscal 2023 Second Quarter Financial Results

Company to Host Conference Call at 9:00 a.m., ET, on February 14, 2023 WALTHAM, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) — Great Elm Group, Inc. (“we,” “our,” “GEG,” or “Great Elm”), (NASDAQ: GEG), an alternative asset manager, today announced financial results for its fiscal second quarter ended December 31, 2022. Transformational Transactions On January 3, 2023, GEG sold its Durable Medical Equipment (“DME”) business for $80 million. After settling all obligations, the transaction resulted in approximately $26 million in net cash proceeds and 346,028 shares of Quipt common stock. On December 30, 2022, GEG entered into an agreement to sell 61% of the equity interests in Forest Investments, Inc. (“Forest”) and on January 17, 2023 it exercised a put right for the remaining 19% of the equity interests in Forest for aggregate cash...

Continue reading

Vornado Announces Fourth Quarter 2022 Financial Results

Vornado Announces Fourth Quarter 2022 Financial Results

NEW YORK, Feb. 13, 2023 (GLOBE NEWSWIRE) — Vornado Realty Trust (NYSE: VNO) reported today: Quarter Ended December 31, 2022 Financial Results NET LOSS attributable to common shareholders for the quarter ended December 31, 2022 was $493,280,000, or $2.57 per diluted share, compared to net income attributable to common shareholders of $11,269,000, or $0.06 per diluted share, for the prior year’s quarter. Adjusting for the items that impact period-to-period comparability listed in the table on the following page, net income attributable to common shareholders, as adjusted (non-GAAP) for the quarter ended December 31, 2022 was $19,954,000, or $0.10 per diluted share, and $22,977,000, or $0.12 per diluted share for the quarter ended December 31, 2021. FUNDS FROM OPERATIONS (“FFO”) attributable to common shareholders...

Continue reading

Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin

Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin

Sale of assets related to Flow Cytometry & Imaging (FCI) Business Unit Acquisition will expand Cytek’s product portfolio to include imaging and menu-based application driven flow cytometry to provide full cell analysis solutions to its customers Transaction is in line with DiaSorin’s strategic priorities communicated to the market after Luminex acquisition Employees associated with commercial, operations, R&D and supporting functions expected to join Cytek SALUGGIA, Italy and FREMONT, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) — DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has signed an agreement with Cytek to sell substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit. The sale...

Continue reading

MDxHealth Announces UnitedHealthcare to Provide Commercial Coverage for the Genomic Prostate Score (GPS) Test

MDxHealth Announces UnitedHealthcare to Provide Commercial Coverage for the Genomic Prostate Score (GPS) Test

NEWS RELEASE 13 FEBRUARY 2023, 4:00PM ET / 22:00 CET UnitedHealthcare singles out mdxheath’s GPS test as its only commercially-covered test to risk stratify men newly diagnosed with localized prostate cancer IRVINE, CA, and HERSTAL, BELGIUM – February 13, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced that UnitedHealthcare will cover the mdxhealth Genomic Prostate Score (GPS) test (formerly Oncotype DX GPS) under UnitedHealthcare’s commercial policies to assist with treatment decisions for individuals newly diagnosed with localized prostate cancer and meeting coverage criteria. Michael K. McGarrity, CEO of mdxhealth, commented: “We are very pleased to announce that UnitedHealthcare, the largest private health insurer in the United States, will provide coverage for our Genomic...

Continue reading

Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.

Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.

SAN DIEGO and PALO ALTO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, together with Sorrento, issued the following statements: Henry Ji, Ph.D., Chairman and Chief Executive Officer of Sorrento, commented: “Today, Sorrento Therapeutics, Inc. and its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc. (“Scintilla”), commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”).  While Scilex is...

Continue reading

<div>RJD Green Inc.'s Management Discusses 2022 Year-End Results and 2023 Growth</div>

RJD Green Inc.’s Management Discusses 2022 Year-End Results and 2023 Growth

Tulsa, OK, Feb. 13, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — RJD Green Inc. (OTCPK: RJDG) CEO Ron Brewer updates shareholders on 2022 year-end results and targeted 2023. Dear Valued RJD Green Shareholders, As we have finished 2022 and are now in 2023, RJD Green’s management team would like to take the opportunity to update all existing and potential shareholders with the latest information on developments with the Company. Please be advised – this letter is not a substitute for reviewing our press releases and SEC filings. Some of this update is opinion – please note the forward-looking statements disclosure. We hope to simplify the complexity and put our latest news items in context and keep you updated on our activities and events that may not rise to the level of a press release or SEC filing. We continue to work...

Continue reading

ILUS Confirms the Incorporation of Its Defense Subsidiary, Hyperion Defense Solutions

ILUS Confirms the Incorporation of Its Defense Subsidiary, Hyperion Defense Solutions

NEW YORK, NY, Feb. 13, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – ILUS International Inc. (OTC: ILUS) is a Mergers and Acquisitions company focused on acquiring and growing companies in the public safety, industrial, defense and renewable sectors. The company has incorporated Hyperion Defense Solutions to roll out its defense sector growth through several acquisitions and partnerships which are currently in progress. ILUS co-founded Hyperion Defense Solutions (Hyperion) alongside two experienced and esteemed British military veterans, Chris Derbyshire, and Tim Grey. Through their combined 34 years of military service and 22 years holding senior roles in the defense sector, they have amassed a wealth of technical expertise and senior level contacts as well as an acute understanding of defense customer requirements and military...

Continue reading

SEER’S MV TECHNOLOGIES RECEIVES CONTRACTS FOR MORE THAN $2MM

SEER’S MV TECHNOLOGIES RECEIVES CONTRACTS FOR MORE THAN $2MM

COVERING MEDIA REPLACEMENT AND FIVE RENEWABLE BIOGAS PROJECTS IN CANADA AND THE US MV HAS $22 MILLION IN PROJECT BIDS OUTSTANDING MV Technologies contracts to design and install its H2S removal systems in five new biogas/RNG projects and recently received a new contract to replace approximately $600,000 of media annually in addition to its ongoing annual replacement media requirements of over $1.2MM. Currently, MV has outstanding biogas project bids valued at approximately $22MM for additional systems worldwide. BROOMFIELD, CO, Feb. 13, 2023 (GLOBE NEWSWIRE) — Strategic Environmental & Energy Resources, Inc. (SEER) (OTCQB: SENR), a provider of environmental, renewable fuels and industrial waste stream management services, has been recently awarded multiple purchase orders totaling more than $1.5M for the design and installation...

Continue reading

Genius Group Releases Schedule of Shareholder Actions

Genius Group Releases Schedule of Shareholder Actions

SINGAPORE, Feb. 13, 2023 (GLOBE NEWSWIRE) — Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, releases today a schedule of shareholder actions: Wednesday, February 15th, 4.15pm EST: Virtual Investor Meeting The Company’s CEO, Roger Hamilton, will hold a virtual investor meeting to provide Investors with an update on the company, including an overview of Genius Group’s curriculum, Metaversity & A.I. development plans, details of the Company’s recently spin-off of Entrepreneur Resorts Ltd, the process for shareholders to follow to redeem their $10 per share NFT coupons and an opportunity to answer questions and respond to shareholder enquiries. A press release with details about the virtual investor meeting was released on February 6th, 2023 and can...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.